MNG334
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.596
- MYC_TARGETS_V2+0.540
- TNFA_SIGNALING_VIA_NFKB+0.504
- E2F_TARGETS+0.412
- G2M_CHECKPOINT+0.380
- UV_RESPONSE_UP+0.325
- ANGIOGENESIS+0.294
- MYC_TARGETS_V1+0.288
- ADIPOGENESIS+0.250
- ESTROGEN_RESPONSE_LATE+0.218
Top 10 suppressed
- PROTEIN_SECRETION-0.366
- INTERFERON_ALPHA_RESPONSE-0.224
- PI3K_AKT_MTOR_SIGNALING-0.198
- BILE_ACID_METABOLISM-0.197
- APICAL_SURFACE-0.160
- COMPLEMENT-0.148
- INTERFERON_GAMMA_RESPONSE-0.119
- PEROXISOME-0.113
- MITOTIC_SPINDLE-0.109
- UV_RESPONSE_DN-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013551 | — | cohortSQ1 | 0.778 |
| 2 | b038a717-19be-40c4-a4df-992156b5e2a2 | — | — | 0.745 |
| 3 | MNG1115 | — | — | 0.732 |
| 4 | MDT-AP-0549 | Med | Medulloblastoma | 0.730 |
| 5 | TCGA-PQ-A6FN-01A-11R-A31N-07 | — | — | 0.723 |
| 6 | TCGA-DK-A2I6-01A-12R-A18C-07 | — | — | 0.710 |
| 7 | SRR975592 | — | — | 0.710 |
| 8 | MNG437 | — | — | 0.705 |
| 9 | MNG1082 | — | — | 0.704 |
| 10 | MDT-AP-0370 | Med | Medulloblastoma | 0.685 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.596 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.504 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.412 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.325 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.294 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.288 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.218 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.174 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.152 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.147 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.121 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.112 | Binimetinib | — uncovered |
| HYPOXIA | 0.106 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.105 | Idelalisib | — uncovered |
| MYOGENESIS | 0.101 | Inavolisib | — uncovered |